Engineering reduced-immunogenicity enzymes for amino acid depletion therapy in cancer

Methods in Enzymology

Volumn 502, Issue , 2012, Pages 291-319

  Cantor, Jason R ^a   Panayiotou, Vasiliki ^a   Agnello, Giulia ^b   Georgiou, George ^a,b   Stone, Everett M ^a  

^a The University of Texas at Austin   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Chemotherapeutic; Engineering; Enzymes; Immunogenicity

Indexed keywords

AMINO ACID; ARGININE; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; EPITOPE; ISOENZYME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MANGANESE; T LYMPHOCYTE RECEPTOR;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER THERAPY; CELL METABOLISM; CHEMICAL STRUCTURE; COMPUTER MODEL; DRUG DESIGN; ENZYME DEGRADATION; ENZYME ENGINEERING; ESCHERICHIA COLI; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEPLETION; SCREENING TEST; T LYMPHOCYTE;

ANIMALIA; ESCHERICHIA;

EID: 84855410026     PISSN: 00766879     EISSN: 15577988     Source Type: Book Series    
DOI: 10.1016/B978-0-12-416039-2.00015-X     Document Type: Chapter

References (125)

1. D.D. Anthony, and P.V. Lehmann T-cell epitope mapping using the ELISPOT approach Methods 29 2003 260 269 (Pubitemid 36513442)
2. P.A. Ascierto Pegylated arginine deiminase treatment of patients with metastatic melanoma: Results from phase I and II studies J. Clin. Oncol. 23 2005 7660 7668 (Pubitemid 46291831)
3. H. Ashe N5-methyltetrahydrofolate: Homocysteine methyltransferase activity in extracts from normal, malignant and embryonic tissue culture cells Biochem. Biophys. Res. Commun. 57 1974 417
4. B.L. Asselin The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia Adv. Exp. Med. Biol. 457 1999 621
5. D.S. Auld, and B.L. Vallee Kinetics of carboxypeptidase A. pH dependence of tripeptide hydrolysis catalyzed by zinc, cobalt, and manganese enzymes Biochemistry 9 1970 4352 4359
6. V.I. Avramis, and E.H. Panosyan Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: The past, the present and recommendations for the future Clin. Pharmacokinet. 44 2005 367 393 (Pubitemid 40663683)
7. M.P. Baker, and T.D. Jones Identification and removal of immunogenicity in therapeutic proteins Curr. Opin. Drug Discov. Devel. 10 2007 219 227 (Pubitemid 46442221)
8. N.H. Bander Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer J. Clin. Oncol. 23 2005 4591 4601 (Pubitemid 46224061)
9. R.N. Beale, and D. Croft A sensitive method for the colorimetric determination of urea J. Clin. Pathol. 14 1961 418 424
10. S.J. Benkovic, and S. Hammes-Schiffer A perspective on enzyme catalysis Science 301 2003 1196 1202 (Pubitemid 37052200)
11. J.R. Bertino Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: Current strategies Cancer Biol. Ther. 11 2011 627 632
12. B.R. Bickmore Bond-valence methods for pKa prediction. II. Bond-valence, electrostatic, molecular geometry, and solvation effects Geochim. Cosmochim. Acta 70 2006 4057 4071 (Pubitemid 44201719)
13. B.P. Bode Molecular and functional analysis of glutamine uptake in human hepatoma and liver-derived cells Am. J. Physiol. Gastrointest. Liver Physiol. 283 2002 G1062
14. R.E. Bontrop Major histocompatibility complex class II polymorphisms in primates Immunol. Rev. 167 1999 339 350 (Pubitemid 29178992)
15. T.L. Bowles Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase Int. J. Cancer 123 2008 1950 1955
16. R.A. Cairns Regulation of cancer cell metabolism Nat. Rev. Cancer 11 2011 85 95
17. E. Cama Structural and functional importance of first-shell metal ligands in the binuclear manganese cluster of arginase I Biochemistry 42 2003 7748 7758 (Pubitemid 36758940)
18. J.R. Cantor The human asparaginase-like protein 1 hASRGL1 is an Ntn hydrolase with beta-aspartyl peptidase activity Biochemistry 48 2009 11026 11031
19. J.R. Cantor Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift Proc. Natl. Acad. Sci. USA 108 2011 1272 1277
20. H. Cao Influence of L-methionine-deprived total parenteral nutrition with 5-fluorouracil on gastric cancer and host metabolism World J. Gastroenterol. 7 2001 698 701
21. R.L. Capizzi L-asparaginase: Clinical, biochemical, pharmacological, and immunological studies Ann. Intern. Med. 74 1971 893 901
22. E. Cellarier Methionine dependency and cancer treatment Cancer Treat. Rev. 29 2003 489 499 (Pubitemid 37428321)
23. S. Chaberek Jr. Stability of metal chelates. II. β- Hydroxyethyliminodiacetic acid J. Am. Chem. Soc. 74 1952 5057 5060
24. P.N. Cheng Remission of hepatocellular carcinoma with arginine depletion induced by systemic release of endogenous hepatic arginase due to transhepatic arterial embolisation, augmented by high-dose insulin: Arginase as a potential drug candidate for hepatocellular carcinoma Cancer Lett. 224 2005 67 80 (Pubitemid 40720368)
25. P.N.M. Cheng Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion Cancer Res. 67 2007 309
26. D.A. Cooney, and R.E. Handschumacher L-asparaginase and L-asparagine metabolism Annu. Rev. Pharmacol. 10 1970 421 440
27. A.P. Cope T cell responses to a human cartilage autoantigen in the context of rheumatoid arthritis-associated and nonassociated HLA-DR4 alleles Arthritis Rheum. 42 1999 1497 1507 (Pubitemid 30265609)
28. B.J. Dillon Biochemical characterization of the arginine degrading enzymes arginase and arginine deiminase and their effect on nitric oxide production Med. Sci. Monit. 8 2002 BR248 BR253
29. B.J. Dillon Incidence and distribution of argininosuccinate synthetase deficiency in human cancers Cancer 100 2004 826 833
30. P.A. Dinndorf FDA drug approval summary: Pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL) Oncologist 12 2007 991 998 (Pubitemid 47359142)
31. J.D. Donaldson, and D. Beyersmann Encyclopedia of industrial chemistry F. Stephen Yamamoto, Y. Thomas Campbell, James F. Rounsaville, Ullman's Encyclopedia of Industrial Chemistry 1985 Publication Information Weinheim Federal Republic of Germany: VCH Verlagsgesellschaft; Deerfield Beach, FL, USA: VCH Publishers Edition 5th, completely rev. ed.
32. M.T. Dorak Unravelling an HLA-DR association in childhood acute lymphoblastic leukemia Blood 94 1999 694
33. D.P. Dowling Evolution of the arginase fold and functional diversity Cell. Mol. Life Sci. 99 2008 82734 2739
34. M. Duval Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: Results of a randomized European Organisation for Research and Treatment of Cancer - Children's Leukemia Group phase 3 trial Blood 99 2002 2734
35. C.M. Ensor Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo Cancer Res. 62 2002 5443 5450
36. D.E. Epner Can dietary methionine restriction increase the effectiveness of chemotherapy in treatment of advanced cancer? J. Am. Coll. Nutr. 20 2001 443
37. L.G. Feun Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors J. Neurooncol. 82 2007 177 181 (Pubitemid 46431862)
38. C.S. Fishburn The pharmacology of PEGylation: Balancing PD with PK to generate novel therapeutics J. Pharm. Sci. 97 2008 4167 4183
39. Y.M. Fu, and G.G. Meadows Specific amino acid dependency regulates the cellular behavior of melanoma J. Nutr. 137 2007 1591S
40. C.H. Fu, and K.M. Sakamoto PEG-asparaginase Expert Opin. Pharmacother. 8 2007 1977 1984 (Pubitemid 47316151)
41. Y.M. Fu Specific amino acid dependency regulates invasiveness and viability of androgen-independent prostate cancer cells Nutr. Cancer 45 2003 60 73
42. E.S. Glazer Phase II study of pegylated arginine deiminase for non-resectable and metastatic hepatocellular carcinoma JCO 28 2010 2220 2226
43. H. Gong Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis Leukemia 14 2000 826 829 (Pubitemid 30235059)
44. N. Goseki Synergistic effect of methionine-depleting total parenteral nutrition with 5-fluorouracil on human gastric cancer: A randomized, prospective clinical trial Jpn. J. Cancer Res. 86 1995 484 489
45. D.A. Guertin, and D.M. Sabatini Defining the role of mTOR in cancer Cancer Cell 12 2007 9 22 (Pubitemid 47001784)
46. B.C. Halpern The effect of replacement of methionine by homocystine on survival of malignant and normal adult mammalian cells in culture Proc. Natl. Acad. Sci. 71 1974 1133 1136
47. F.A. Harding A beta-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy Mol. Cancer Ther. 4 2005 1791 1800 (Pubitemid 41685314)
48. C.M. Haskell, and G.P. Canellos Asparaginase and leukaemia Lancet 1 1969 626
49. C.M. Haskell, and G.P. Canellos L-asparaginase resistance in human leukemia-asparagine synthetase Biochem. Pharmacol. 18 1969 2578
50. C.M. Haskell Biochemical and pharmacologic effects of L-asparaginase in man J. Lab. Clin. Med. 75 1970 763 770
51. N. Hay, and N. Sonenberg Upstream and downstream of mTOR Genes Dev. 18 2004 1926
52. C. He, and S.J. Lippard Aminoguanidinium hydrolysis effected by a hydroxo-bridged dicobalt (II) complex as a functional model for arginase and catalyzed by mononuclear cobalt (II) complexes J. Am. Chem. Soc. 120 1998 105 113 (Pubitemid 28046434)
53. C.P. Hernandez Pegylated arginase I: A potential therapeutic approach in T-ALL Blood 115 2010 5214 5221
54. D.H. Ho L-asparagine requirement and the effect of L-asparaginase on the normal and leukemic human bone marrow Cancer Res. 30 1970 466 472
55. R.G. Holgate, and M.P. Baker Circumventing immunogenicity in the development of therapeutic antibodies IDrugs 12 2009 233 237
56. L. Hong, and W. Fast Inhibition of human dimethylarginine dimethylaminohydrolase-1 by S-nitroso-L-homocysteine and hydrogen peroxide J. Biol. Chem. 282 2007 34684
57. B. Horowitz Asparagine synthetase activity of mouse leukemias Science 160 1968 533 535
58. J. Huang The kinetics of two-dimensional TCR and pMHC interactions determine T-cell responsiveness Nature 464 2010 932 936
59. H. Inaba Thyrotropin receptor epitopes and their relation to histocompatibility leukocyte antigen-DR molecules in Graves' disease J. Clin. Endocrinol. Metab. 91 2006 2286 2294 (Pubitemid 43855019)
60. H. Irving, and R.J.P. Williams Order of stability of metal complexes Nature 162 1948 746 747
61. F. Izzo Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: Results from phase I/II studies J. Clin. Oncol. 22 2004 1815 1822 (Pubitemid 41095171)
62. A. Jemal Global cancer statistics CA: Cancer J. Clin. 61 2011 69 90 caac. 20107v1
63. T.D. Jones The development of a modified human IFN-alpha2b linked to the Fc portion of human IgG1 as a novel potential therapeutic for the treatment of hepatitis C virus infection J. Interferon Cytokine Res. 24 2004 560 572 (Pubitemid 39244545)
64. T.D. Jones Identification and removal of a promiscuous CD4 + T cell epitope from the C1 domain of factor VIII J. Thromb. Haemost. 3 2005 991 1000 (Pubitemid 41632831)
65. E.Y. Jones MHC class II proteins and disease: A structural perspective Nat. Rev. Immunol. 6 2006 271 282
66. P.L. Kearney Kinetic characterization of protein arginine deiminase 4: A transcriptional corepressor implicated in the onset and progression of rheumatoid arthritis Biochemistry 44 2005 10570 10582 (Pubitemid 41098234)
67. M. Khare HLA class II transgenic mice authenticate restriction of myelin oligodendrocyte glycoprotein-specific immune response implicated in multiple sclerosis pathogenesis Int. Immunol. 15 2003 535 546 (Pubitemid 36432406)
68. W. Kim Trends in enzyme therapy for phenylketonuria Mol. Ther. 10 2004 220 224 (Pubitemid 39117867)
69. J.L. Klitgaard Reduced susceptibility of recombinant polyclonal antibodies to inhibitory anti-variable domain antibody responses J. Immunol. 177 2006 3782 3790 (Pubitemid 44359911)
70. D.M. Kokkinakis Effect of long-term depletion of plasma methionine on the growth and survival of human brain tumor xenografts in athymic mice Nutr. Cancer 29 1997 195 204 (Pubitemid 28063271)
71. E. Koren Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein Clin. Immunol. 124 2007 26 32 (Pubitemid 46938690)
72. G. Kroemer, and J. Pouyssegur Tumor cell metabolism: Cancer's Achilles' heel Cancer Cell 13 2008 472 482 (Pubitemid 351766797)
73. B. Leader Protein therapeutics: A summary and pharmacological classification Nat. Rev. Drug Discov. 7 2008 21 39
74. V.K. Lishko Depletion of serum methionine by methioninase in mice Anticancer Res. 13 1993 1465
75. P.L. Lorenzi Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines Mol. Cancer Ther. 7 2008 3123
76. D.J. Macfarlane Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99mTc-DI-DD-3B6/22-80B3 Fab′ Eur. J. Nucl. Med. Mol. Imaging 33 2006 648 656
77. S. Man Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2.1 transgenic mice Int. Immunol. 7 1995 597 605
78. S. Mazurek, and E. Eigenbrodt The tumor metabolome Anticancer Res. 23 2003 1149 1154 (Pubitemid 36750932)
79. D.J. McGee Purification and characterization of Helicobacter pylori arginase, RocF: Unique features among the arginase superfamily Eur. J. Biochem. 271 2004 1952 1962 (Pubitemid 38657347)
80. M.A. Medina Relevance of glutamine metabolism to tumor cell growth Mol. Cell. Biochem. 113 1992 1 15
81. A.J. Meijer Amino acids as regulators and components of nonproteinogenic pathways J. Nutr. 133 2003 2057S
82. M. Nakayama-Hamada Comparison of enzymatic properties between hPADI2 and hPADI4 Biochem. Biophys. Res. Commun. 327 2005 192 200 (Pubitemid 40051370)
83. H. Nawashiro L type amino acid transporter 1 as a potential molecular target in human astrocytic tumors Int. J. Cancer 119 2006 484 492 (Pubitemid 43955699)
84. Y. Ni Arginine deiminase, a potential anti-tumor drug Cancer Lett. 261 2008 1 11
85. A.S. Parker Optimization algorithms for functional deimmunization of therapeutic proteins BMC Bioinformatics 11 2010 180
86. S.K. Pavelic Metastasis: New perspectives on an old problem Mol. Cancer 10 2011 22
87. D.D. Perrin 421. The hydrolysis of manganese (II) ion J. Chem. Soc. 1962 1962 2197 2200 (Resumed)
88. C.G. Proud Regulation of mammalian translation factors by nutrients Eur. J. Biochem. 269 2002 5338 5349 (Pubitemid 35365523)
89. N.G. Richards, and M.S. Kilberg Asparagine synthetase chemotherapy Annu. Rev. Biochem. 75 2006 629 654 (Pubitemid 44118046)
90. N. Savaraj Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma Curr. Mol. Med. 10 2011 405 412
91. L. Scott Single amino acid (arginine) deprivation: Rapid and selective death of cultured transformed and malignant cells Br. J. Cancer 83 2000 800 810
92. L.J. Shen Modulation of arginine metabolic pathways as the potential anti-tumor mechanism of recombinant arginine deiminase Cancer Lett. 231 2006 30 35
93. M. Shirai CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1 J. Immunol. 154 1995 2733 2742
94. S.P. Stabler Quantitation of total homocysteine, total cysteine, and methionine in normal serum and urine using capillary gas chromatography-mass spectrometry Anal. Biochem. 162 1987 185 196 (Pubitemid 17064318)
95. A.C. Steere Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide J. Exp. Med. 203 2006 961 971
96. E.M. Stone Characterization of a transient covalent adduct formed during dimethylarginine dimethylaminohydrolase catalysis Biochemistry 44 2005 7069 7078 (Pubitemid 40632424)
97. E.M. Stone Inactivation of two diverse enzymes in the amidinotransferase superfamily by 2-chloroacetamidine: Dimethylargininase and peptidylarginine deiminase Biochemistry 44 2005 13744 13752 (Pubitemid 41507455)
98. E. Stone Replacing Mn2 + with Co2 + in human arginase I enhances cytotoxicity towards L-arginine auxotrophic cancer cell lines ACS Chem. Biol. 5 2010 333 342
99. E.M. Stone The second shell metal ligands of human arginase affect coordination of nucleophile and substrate Biochemistry 49 2010 10582 10588
100. M.D. Story L-asparaginase kills lymphoma cells by apoptosis Cancer Chemother. Pharmacol. 32 1993 129 133 (Pubitemid 23131932)
101. Y. Tan Anticancer efficacy of methioninase in vivo Anticancer Res. 16 1996 3931 3936 (Pubitemid 27084947)
102. Y. Tan Serum methionine depletion without side effects by methioninase in metastatic breast cancer patients Anticancer Res. 16 1996 3937 3942 (Pubitemid 27084948)
103. Y. Tan Overexpression and large-scale production of recombinant L-methionine-a-deamino-g-mercaptomethane-lyase for novel anticancer therapy Protein Expr. Purif. 9 1997 233 245 (Pubitemid 27210719)
104. Y. Tan Recombinant methioninase infusion reduces the biochemical endpoint of serum methionine with minimal toxicity in high-stage cancer patients Anticancer Res. 17 1997 3857 3860 (Pubitemid 28014950)
105. Y. Tan Broad selective efficacy of recombinant methioninase and polyethylene glycol-modified recombinant methioninase on cancer cells in vitro Anticancer Res. 30 2010 1041
106. S. Tangri Rationally engineered therapeutic proteins with reduced immunogenicity J. Immunol. 174 2005 3187 3196 (Pubitemid 40354020)
107. T. Ueno Cell cycle arrest and apoptosis of leukemia cells induced by L-asparaginase Leukemia 11 1997 1858 1861 (Pubitemid 27485130)
108. M. Ueta Immunosuppressive properties of human amniotic membrane for mixed lymphocyte reaction Clin. Exp. Immunol. 129 2002 464 470 (Pubitemid 35024915)
109. M. Wang Engineering an arginine catabolizing bioconjugate: Biochemical and pharmacological characterization of PEGylated derivatives of arginine deiminase from Mycoplasma arthritidis Bioconjug. Chem. 17 2006 1447 1459 (Pubitemid 44851489)
110. P. Wang A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach PLoS Comput. Biol. 4 2008 e1000048
111. Y. Wang Developing dual and specific inhibitors of dimethylarginine dimethylaminohydrolase-1 and nitric oxide synthase: Toward a targeted polypharmacology to control nitric oxide Biochemistry 48 2009 8624 8635
112. O. Warburg The metabolism of tumors in the body J. Gen. Physiol. 8 1927 519
113. P.A.M. Warmerdam Elimination of a human T-cell region in staphylokinase by T-cell screening and computer modeling Thromb. Haemost. 87 2002 666 673 (Pubitemid 34302956)
114. M. Wasa Adaptive regulation of amino acid transport in nutrient-deprived human hepatomas Am. J. Surg. 171 1996 163 169 (Pubitemid 26028213)
115. D.N. Wheatley, and E. Campbell Arginine catabolism, liver extracts and cancer Pathol. Oncol. Res. 8 2002 18 25 (Pubitemid 34532775)
116. S.S. Winter Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: A report of POG study 9296 Pediatr. Blood Cancer 46 2006 179 186 (Pubitemid 43076068)
117. S. Wullschleger TOR signaling in growth and metabolism Cell 124 2006 471 484 (Pubitemid 43199434)
118. Z. Yang Circulating half-life of PEGylated recombinant methioninase holoenzyme is highly dose dependent on cofactor pyridoxal-5′-phosphate Cancer Res. 64 2004 5775
119. Z. Yang PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates AACR 64 2004 6673 6678 (Pubitemid 39297929)
120. Z. Yang Pharmacokinetics, methionine depletion, and antigenicity of recombinant methioninase in primates Clin. Cancer Res. 10 2004 2131
121. T.S. Yang A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients Br. J. Cancer 103 2010 954 960
122. V.P. Yeung Elimination of an immunodominant CD4 + T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope J. Immunol. 172 2004 6658 6665 (Pubitemid 38669101)
123. T. Yoshioka Anticancer efficacy in vivo and in vitro, synergy with 5-fluorouracil, and safety of recombinant methioninase Cancer Res. 58 1998 2583 2587 (Pubitemid 28275429)
124. A. Zeidan Pegasparaginase: Where do we stand? Expert Opin. Biol. Ther. 9 2009 111 119
125. L. Zhu A potential antitumor drug (arginine deiminase) reengineered for efficient operation under physiological conditions Chembiochem 11 2010 2294 2301